Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform.
Sauman Singh-PhulgendaRishikesh KumarPrabin DahalAbdalla MunirSumayyah RashanRutuja ChhajedCaitlin NaylorBrittany J MaguireNiyamat Ali SiddiquiEli HarrissManju RahiFabiana AlvesShyam SundarKasia StepniewskaAhmed MusaPhilippe J GuerinKrishna PandeyPublished in: PLoS neglected tropical diseases (2024)
Our review identified studies with very limited sample size for the three major drugs (miltefosine, L-AmB, and pentavalent antimony), while the number of patients combined across studies suggest that the IPD platform would be valuable. With the support of relevant stakeholders, the global PKDL community and sufficient financing, a PKDL IPD platform can be realised. This will allow for exploration of different aspects of treatment safety and efficacy, which can potentially guide future healthcare decisions and clinical practices.
Keyphrases
- healthcare
- clinical trial
- high throughput
- end stage renal disease
- ejection fraction
- newly diagnosed
- mental health
- electronic health record
- prognostic factors
- randomized controlled trial
- big data
- study protocol
- deep learning
- open label
- artificial intelligence
- data analysis
- health information
- replacement therapy
- double blind
- affordable care act